Why We Should Not Treat SMM

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Why We Should Not Treat SMM

By PleXus Communications FEATURING Ben Derman

444 views

November 27, 2023

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

631 views

4 months ago

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

402 views

3 months ago

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

870 views

9 months ago

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Scripps Health

M. Gertz

521 views

7 months ago

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Indy Hematology Review

M. Gertz

714 views

1 year ago

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy & Safe…

Insights from 2023 ASH Annual Meeting

O. Landgren

284 views

11 months ago

Emerging and Current Treatment of MM: What Should We Know and What S…

Indy Hematology Review

K. Anderson

652 views

1 year ago

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Yale Cancer Center

A. Chari

525 views

1 year ago

SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …

5th SOHO Italy Annual Conference

K. Anderson

251 views

11 months ago

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Dana-Farber Cancer Institute

Y. Liu

90 views

4 months ago

Oncologists' Guidance on Treating Smoldering Myeloma: Panel Discussi…

GRACE

A. Goodman, A. Taneja, T. Phillips

133 views

8 months ago

Management of Smoldering Myeloma

XV Eurasian Hematology-Oncology Congress - EHOC 2024

C. Cerchione

60 views

2 months ago

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering Multi…

Insights from 2023 ASH Annual Meeting

S. Thorsteinsdottir

165 views

11 months ago

SOHO 2023 DEBATE: Smoldering MM - Time to Watch and Wait

SOHO 2023 Eleventh Annual Meeting

A. Dispenzieri

117 views

1 year ago

New

Smoldering Myeloma: If and When to Treat

Victor Jimenez Zepeda

48 views

3 weeks ago

SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…

5th SOHO Italy Annual Conference

I. Ghobrial

84 views

11 months ago

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

SOHO 2022 Tenth Annual Meeting

T. Martin

232 views

2 years ago

Myeloma 2022: Challenges and Path Forward

UChicago Medicine

A. Jakubowiak

557 views

2 years ago

ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and Dexam…

Insights from 2023 ASH Annual Meeting

O. Nadeem

92 views

11 months ago

Myeloma Rounds: Asymptomatic Patient With High-Risk SMM

PleXus Communications

N. Antao, P. Hagen

114 views

11 months ago

AUTOPLAY

Login

Login

Join VuMedi

Why We Should Not Treat SMM

A proven CD123 targeted therapy for BPDCN

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Recommended

Advances in Multiple Myeloma 2024: From Bench to Bedside

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy & Safe…

Emerging and Current Treatment of MM: What Should We Know and What S…

Myeloma in 2023: So Many Drugs, Yet So Few Cures

SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Oncologists' Guidance on Treating Smoldering Myeloma: Panel Discussi…

Management of Smoldering Myeloma

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering Multi…

SOHO 2023 DEBATE: Smoldering MM - Time to Watch and Wait

Smoldering Myeloma: If and When to Treat

SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Myeloma 2022: Challenges and Path Forward

ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and Dexam…

Myeloma Rounds: Asymptomatic Patient With High-Risk SMM